Since there were no 11 homozygotes, the comparison was between 12 heterozygotes and 22 homozygotes. These results are shown in Figure 1e . The dopamine D 2 receptor density was significantly lower in heterozygotes vs homozygotes. Laruelle et al 2 
reported their results only by A1
+ vs A1 − alleles (see dot and square in Figure 1f ). However, they did note that there were four A1/A1 homozygotes and they had the highest receptor-binding potential of any of the genotypes (284 ± 61 ml g −1 ). Removing these from the A1
+ group results in lowering the mean D 2 receptor-binding potential for the total 12 heterozygotes from 230 ml g −1 to 220.6 ml g −1 . These results, shown in Figure 1f , are compatible with negative molecular heterosis. Based on the suggestion of Hitzeman 3 that the results for controls would be more accurate than those for schizophrenics, I have estimated what the results might be for the controls only. I was able to do this because the authors of the Laruelle et al 2 study were kind enough to tell me that of the four 11 homozygotes, three were in the control group while one was in the schizophrenia group. Removing those three from the A1 + group resulted in a mean D 2 receptor-binding potential for the 12 heterozygotes of 201 ml g −1 and an average for the 11 homozygotes of 284 ml g . These results, shown in Figure 1g , are even more compatible with molecular heterosis compared to when the schizophrenia cases are included. In fact, the striking differences between the controls and schizophrenics suggest that perhaps schizophrenia is characterized by a lack of a heterosis effect at the DRD2 gene. To examine this, I have also plotted the results in the schizophrenia group by genotype assuming that the one remaining 11 schizophrenic homozygote had a receptor-binding potential of approximately of 283 ml g −1 . Figure 1h shows the results. These data suggest that molecular heterosis at the DRD2 locus appears not to occur in schizophrenia. If the lack of molecular heterosis at the DRD2 gene was due to the disease rather than an artifact due to prior neuroleptic exposure, it could be an important finding for schizophrenia. The potential relevance of molecular heterosis to the interpretation of the role of the DRD2 in alcoholism has been presented elsewhere. 4 Molecular heterosis is not rare. We have reviewed its presence at other gene loci including DRD1, DRD3, DRD4, ADR2AC, HTR2A, HTT, HLA, ␣-CAMKII, ESR, secretor, C3 complement, properdinB, ␤-globin, and haptoglobin genes (unpublished). Molecular heterosis is counter-intuitive since one would expect that if one allele is associated with a lower level of gene expression, it should be lower in homozygotes than in heterozygotes. For receptors, one explanation could be that the range of expression of the receptor on the surface of neurons is much greater in heterozygotes and over the period of time from conception to adolescence and adulthood that could lead to a greater range of resilience or responsiveness for different outcomes or phenotypes. The most reliable way to confirm or exclude the presence of molecular heterosis would be to accumulate more PET or SPECT data on the levels of the striatal D 2 receptor in 11 homozygotes.
If an absence of molecular heterosis at the DRD2 gene is characteristic of schizophrenia, and further studies verify such a difference between controls and schizophrenics, identifying the mechanism would be important. Lynch and Walsh 8 cited the important role of genetic background in heterosis, and the difference between controls and schizophrenics could be due to their different genetic backgrounds.
Based on the analyses presented here I propose that the differences between the Pohjalainen et al 1 and Laruelle et al 2 studies are due primarily to a failure to consider the effect of molecular heterosis. When heterosis is considered, the results suggest that the TaqI A1/A2 genotypes of the DRD2 gene do correlate with dopamine D 2 receptor density, and that schizophrenia may be characterized by a loss of this effect. The ability of the TaqI A polymorphism, located 3Ј to the DRD2 gene, to effect gene function may be because it is in linkage disequilibrium with a minisatellite polymorphism. 9 The studies of Paquette et al 10 have shown that the effect of minisatellite polymorphisms on gene function can occur over considerable distances.
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Evidence for an association between heroin dependence and a VNTR polymorphism at the serotonin transporter locus SIR -Substance abuse is a very complex disorder. Although it is commonly accepted that environmental influences are the primary factors leading to substance abuse and addiction, there is strong consensus for some genetic contribution to the etiopathology involved. For example, there is evidence that personality traits such as novelty seeking are inherited. 1 Association studies with candidate genes aim to dissect and identify important genetic factors contributing to such noveltyseeking behavior. As abnormalities in the dopami-nergic reward pathways are thought to be involved in substance abuse and addictive behaviors, the search for candidate genes has concentrated on the dopamine receptors including the D1 receptor, 2 D2 receptor, 3,4 D3 receptor, 5 D4 receptor [6] [7] [8] and D5 receptor. 9 Recently, investigation has been extended to the ␣ 2A AR adrenergic receptor 10 and the cannabinoid receptor.
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In this study, we examined the association of one of the polymorphisms in the 5-hydroxytryptamine transporter (5-HTT) gene to heroin dependence in individuals of Chinese descent in Singapore. We chose the serotonin transporter as it is a principal site of action of selective serotonin reuptake inhibitors (SSRIs). SSRIs are widely used in the treatment of psychiatric disorders and substance abuse and this transporter is involved in concentrating neurotoxins and substituted amphetamines in 5-HT neurons. 12 There is evidence of dysfunction of serotonergic systems in the pathophysiology of substance addiction. Among the several polymorphisms identified in the serotonin transporter (5-HTT) gene, specific alleles of a variable number tandem repeat (VNTR) in the second intron have been reported to be associated with affective disorder. 12, 13 Previous studies of this VNTR in the second intron of the 5-HTT gene have identified three alleles: 9, 10 and 12 copies of a 16-17 base pair element. Our data indicated significant difference in allelic and genotype frequencies between case and control groups.
We genotyped a total of 72 unrelated age-matched controls and 63 addicts for this polymorphism. All are resident in Singapore and of Chinese descent. Volunteers for controls were recruited, with informed consent, from university and hospital staff with no history of substance abuse. Patients with opiate addiction were from the hospital's pioneer programme of voluntary detoxification and rehabilitation. All fulfilled the Diagnostic & Statistical Manual 4th Edition (DSM-IV) 14 criteria for substance dependency. They were first seen at the out-patient clinic to assess their drug habit status and their motivation for voluntary detoxification. Informed consent regarding treatment and investigations was then obtained from patients before in-patient drug detoxification was commenced. During the hospitalisation patients were assessed daily with compulsory urine checks. All subjects tested positive for opioids in the urine before treatment and all cases fulfilled DSM-IV criteria for opioid withdrawal in the in-patient assessments.
Genomic DNA was extracted from blood collected in EDTA tubes with Qiagen Blood Kit (Qiagen GmbH, Germany) according to manufacturer's instructions. Sequence of primers and PCR conditions were as previously described. 15 Amplification was carried out in a total volume of 10 l. PCR products were resolved on 3% NuSieve gels. Genotype frequencies, allele frequencies, 2 -tests, Fisher's exact tests, deviation from Hardy-Weinberg equilibrium, and odds ratios (95% confidence intervals) were calculated using SPSS 8 computer programme.
The distribution of genotypes and alleles in control and heroin-dependent subjects is shown in Table 1 . Genotype distribution for the control group conformed to Hardy-Weinberg equilibrium. For both the control and patient groups, only the 10-and 12-repeat alleles are found in our population; thus far, the 9-repeat allele was not encountered in the sample population.
Statistical analysis showed a significant overall association between heroin addiction and the 10-repeat allele with an odds ratio of 3.47 (95% CI 1.4-8.55, P = 0.004). There is a significant excess of both 10/10 and 10/12 genotypes (P = 0.016) and the 10-repeat allele (P = 0.005) for the addicts.
The relative frequencies of the two alleles are also very different from those reported for Caucasians, in which the 10-and 12-repeat alleles have more equitable representations of 0.42 and 0.56 respectively, with the 9-repeat allele at 0.02. 13 In our study population the 10-repeat allele has a frequency of less than 5% in the control group. Interestingly, the relative frequencies reported for the Japanese population fell in between at 0.889 for the 12-repeat allele and 0.111 for the 10-repeat allele, 16 the rare 9-repeat allele was also not found in the Japanese subjects studied.
The observed association raises the question of the causal relationship between the 5-HT transporter and opioid addiction. As the polymorphism is in the intron and no functional difference between the various alleles has been documented, it is possible that this polymorphism is not directly involved but is in linkage disequilibrium with another functional polymorphism within the same gene, although it is not impossible that the polymorphism might influence the processing or stability of the primary transcript. Alternatively, it is also possible that 5-HTT is not directly involved but is in linkage disequilibrium with another nearby locus which is the true susceptibility gene.
Non-functional polymorphisms are frequently used as marker loci in case-control and association studies. Some of the other VNTRs which have been reported to show association with genetic susceptibility to recog-nizable traits include the D4 dopamine receptor (D4DR) [6] [7] [8] (novelty-seeking behavior) and the insulin minisatellite locus (Type I diabetes mellitus). 17 To our knowledge this is the first report of a significant association linking this 5-HT transporter VNTR polymorphism to substance abuse and addiction. We intend to extend this study to other ethnic groups in our population to confirm that the association is universal and not limited to Chinese.
Family-based association analysis of the hSKCa3 potassium channel gene in bipolar disorder SIR -There have been several reports of anticipation in both schizophrenia [1] [2] [3] [4] [5] [6] and bipolar disorder, [7] [8] [9] suggesting the hypothesis that a trinucleotide repeat-containing gene may be etiologically related to these disorders. There is evidence of enlarged CAG repeats in subjects affected with schizophrenia or bipolar disorder [10] [11] [12] and genes containing CAG repeats are good etiologic candidates for investigation. 13, 14 Increases in repeat-DNA copy number are forming the basis for a growing number of human disease mutations 15 and most of the repeats enlarge substantially in the disease state. However, this is not always the case. For example, the locus for spinocerebellar atrophy type 6 (SCA6) contains a CAG repeat whose size shows a continuum from the normal to disease, 16 as does the locus for oculopharyngeal muscle dystrophy. 17 A novel human potassium channel gene hSKCa3 was recently described 18, 19 and advanced as a candidate gene for schizophrenia and bipolar disorder. This class of genes encodes proteins known to influence potassium flux in response to intracellular calcium signals.
20
The rat homologue rSKCa3 is widely expressed in the brain and therefore hSKCa3 is also likely to be expressed in human brain. Chandey et al 18 identified two trinucleotide CAG repeats within the coding region of the hSKCa3 gene. Both of these repeats are polymorphic and the second repeat is highly polymorphic. Chandey et al 18 suggest that minor changes in the length of the CAG repeat may influence the activity of the hSKCa3 channel. Hyperactive hSKCa channels may induce hypoactivity of the NMDA receptors via hyperpolarization of the cell membrane, 20 potentially conferring susceptibility to disease.
Chandey et al 18 studied the locus containing the second CAG repeat within the hSKCa3 gene in unrelated groups of patients and matched controls for both schizophrenia and bipolar disorder. They reported evidence for an association between alleles containing more than 19 CAG repeats and schizophrenia. There was a nonsignificant trend toward an association between bipolar disorder and alleles with longer CAG repeats. It was proposed that hSKCa3 might be etiologically related to both disorders. A second study of the hSKCa3 polymorphism in schizophrenia using a casecontrol design also found an elevated frequency of alleles with CAG repeats greater than 19 21 in subjects with schizophrenia thereby providing modest support for the hypothesis.
We genotyped this locus in a series of 69 pedigrees ascertained for a genetic linkage study of bipolar disorder.
22 Forty-nine pedigrees had genotypes for both parents and 11 had genotype data for one parent. The data were analyzed under two models of affection, including or excluding recurrent major depression with the bipolar phenotype. The bipolar phenotype included bipolar I (BPI), bipolar II (BPII), and schizoaffective-manic (SA-M) disorders. All studies were conducted following approval of the institutional ethics review committee. After informed consent all subjects were interviewed using the Schedule for Affective Disorders and Schizophrenia -Lifetime version. 
